NICE rejects second Alzheimer’s drug but opportunity remains for decision change: GlobalData
NICE's rejection of Kisunla raises cost-effectiveness concerns but future approval remains possible pending further evidence
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.